Results 11 to 20 of about 12,785,139 (351)
The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells
The development of inhibitory antibodies to therapeutic factor VIII is the major complication of replacement therapy in patients with hemophilia A. The first step in the initiation of the anti-factor VIII immune response is factor VIII interaction with ...
Bagirath Gangadharan +6 more
doaj +2 more sources
It has been proposed that von Willebrand factor might affect factor VIII immunogenicity by reducing factor VIII uptake by antigen presenting cells. Here we investigate the interaction of recombinant von Willebrand factor with immature monocyte-derived ...
Nicoletta Sorvillo +8 more
doaj +2 more sources
A large fraction of factor VIII in blood originates from liver sinusoidal endothelial cells although extrahepatic sources also contribute to plasma factor VIII levels.
Diego Zanolini +12 more
doaj +2 more sources
The rising incidence of neutralizing antibodies (inhibitors) against therapeutic factor VIII prompted the conduct of studies to answer the question as to whether this rise is related to the introduction of recombinant factor VIII products.
Johannes Oldenburg +2 more
doaj +2 more sources
Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients
Since 1981, the number of factor VIII units to infuse into patients with hemophilia A in order to achieve adequate circulating factor VIII levels has been calculated using the formula: [body weight(kg)×desired factor VIII increase(%)]/2, assuming a ...
Séverine Henrard +2 more
doaj +2 more sources
It is essential to improve therapies for controlling excessive bleeding in patients with haemorrhagic disorders. As activated blood platelets mediate the primary response to vascular injury, we hypothesize that storage of coagulation Factor VIII within ...
Timothy C Nichols +2 more
exaly +2 more sources
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Savita Rangarajan +2 more
exaly +2 more sources
A critical appraisal of one‐stage and chromogenic assays of factor VIII activity
F. Peyvandi, J. Oldenburg, K. Friedman
exaly +2 more sources
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.
BACKGROUND The goal of gene therapy for patients with hemophilia A is to safely impart long-term stable factor VIII expression that predictably ameliorates bleeding with the use of the lowest possible vector dose.
Lindsey A. George +18 more
semanticscholar +1 more source

